{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:59:51Z","timestamp":1781215191958,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jtct.2026.02.052","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:07:14Z","timestamp":1771952834000},"page":"754.e1-754.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4584-1837","authenticated-orcid":false,"given":"Julia Garcia","family":"Mateo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0297-5920","authenticated-orcid":false,"given":"Anna","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswini M.","family":"Dhawale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-6961","authenticated-orcid":false,"given":"Richard","family":"Newcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Venkatachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Karpinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell W.","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan","family":"Ekstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3943-6608","authenticated-orcid":false,"given":"P. Connor","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jtct.2026.02.052_bib0001","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2026.02.052_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2026.02.052_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.052_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jtct.2026.02.052_bib0005","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.jtct.2026.02.052_bib0006","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.052_bib0007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.02.052_bib0008","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jtct.2024.02.019","article-title":"Clinical outcomes and toxicity in older adults receiving chimeric antigen receptor T cell therapy","volume":"30","author":"Johnson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.052_bib0009","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2022.1044","article-title":"Assessment of hospitalizations and emergency department visits after chimeric antigen receptor T-cell therapy among commercially insured patients","volume":"8","author":"Kenzik","year":"2022","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.jtct.2026.02.052_bib0010","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.052_bib0011","doi-asserted-by":"crossref","first-page":"496.e491","DOI":"10.1016\/j.jtct.2021.02.029","article-title":"Association between baseline patient-reported outcomes and complications of hematopoietic stem cell transplantation","volume":"27","author":"Johnson","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.jtct.2026.02.052_bib0012","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","article-title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.052_bib0013","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.052_bib0014","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1023\/A:1024719104351","article-title":"Validation of the PTSD Checklist-Civilian Version in survivors of bone marrow transplantation","volume":"12","author":"Smith","year":"1999","journal-title":"J Trauma Stress"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.052_bib0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton Symptom Assessment System 25 years later: past, present, and future developments","volume":"53","author":"Hui","year":"2017","journal-title":"J Pain Symptom Manage"},{"issue":"15","key":"10.1016\/j.jtct.2026.02.052_bib0016","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/cncr.28699","article-title":"Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy","volume":"120","author":"Miaskowski","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.052_bib0017","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.1988.00380070082020","article-title":"Clinical symptoms and length of survival in patients with terminal cancer","volume":"148","author":"Reuben","year":"1988","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.052_bib0018","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"10.1016\/j.jtct.2026.02.052_bib0019","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtct.2026.02.052_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00378","article-title":"Multisite randomized trial of inpatient palliative care intervention for patients undergoing hematopoietic stem cell transplantation","author":"El-Jawahri","year":"2025","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.jtct.2026.02.052_bib0021","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1200\/JCO.2017.73.2800","article-title":"Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial","volume":"35","author":"El-Jawahri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.052_bib0022","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.34557","article-title":"Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy","volume":"129","author":"Dhawale","year":"2023","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.jtct.2026.02.052_bib0023","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.052_bib0024","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41375-025-02541-6","article-title":"Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy","volume":"39","author":"Nomiyama","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.02.052_bib0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/JIR.S141033","article-title":"The role of neuroinflammation and neurovascular dysfunction in major depressive disorder","volume":"11","author":"Jeon","year":"2018","journal-title":"J Inflamm Res"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:16:35Z","timestamp":1781212595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726001557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666636726001557"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.052","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}